Eterna Therapeutics Announces Appointment of Dr. Elena Ratner to Board of Directors
Eterna Therapeutics (NASDAQ: ERNA) has appointed Dr. Elena Ratner to its Board of Directors. Dr. Ratner, a Professor at Yale University School of Medicine's Department of Obstetrics, Gynecology, and Reproductive Sciences, will guide Eterna's strategic direction in combating ovarian cancer.
This appointment follows Eterna's recent collaboration with MD Anderson Cancer Center, focusing on developing novel therapies for ovarian and breast cancers. The company's lead candidate, ERNA-101, is a cell therapy designed to enhance immune system response against tumors by improving immune cell infiltration and activation.
Dr. Ratner currently serves as Director of the Discovery to Cure Early Ovarian Cancer Detection program and has received notable recognitions including the 2024 David and Cindy Leffell Clinical Excellence Award. Her research focuses on developing targeted drugs for ovarian cancer and addressing chemotherapy resistance in ovarian and uterine cancers.
Eterna Therapeutics (NASDAQ: ERNA) ha nominato la Dr.ssa Elena Ratner nel suo Consiglio di Amministrazione. La Dr.ssa Ratner, Professore presso la Scuola di Medicina dell'Università di Yale nel Dipartimento di Ostetricia, Ginecologia e Scienze della Riproduzione, guiderà la direzione strategica di Eterna nella lotta contro il cancro ovarico.
Questa nomina segue la recente collaborazione di Eterna con il MD Anderson Cancer Center, incentrata sullo sviluppo di nuove terapie per i tumori ovarici e mammari. Il candidato principale dell'azienda, ERNA-101, è una terapia cellulare progettata per migliorare la risposta del sistema immunitario contro i tumori, aumentando l'infiltrazione e l'attivazione delle cellule immunitarie.
La Dr.ssa Ratner attualmente ricopre il ruolo di Direttore del programma Discovery to Cure Early Ovarian Cancer Detection e ha ricevuto riconoscimenti notevoli, tra cui il 2024 David and Cindy Leffell Clinical Excellence Award. La sua ricerca si concentra sullo sviluppo di farmaci mirati per il cancro ovarico e sull'affrontare la resistenza alla chemioterapia nei tumori ovarici e uterini.
Eterna Therapeutics (NASDAQ: ERNA) ha nombrado a la Dra. Elena Ratner en su Junta Directiva. La Dra. Ratner, profesora en la Escuela de Medicina de la Universidad de Yale en el Departamento de Obstetricia, Ginecología y Ciencias de la Reproducción, guiará la dirección estratégica de Eterna en la lucha contra el cáncer de ovario.
Este nombramiento sigue a la reciente colaboración de Eterna con el MD Anderson Cancer Center, centrada en el desarrollo de nuevas terapias para los cánceres de ovario y mama. El candidato principal de la empresa, ERNA-101, es una terapia celular diseñada para mejorar la respuesta del sistema inmunológico contra los tumores al aumentar la infiltración y activación de las células inmunitarias.
La Dra. Ratner actualmente se desempeña como Directora del programa Discovery to Cure Early Ovarian Cancer Detection y ha recibido distinciones notables, incluido el 2024 David and Cindy Leffell Clinical Excellence Award. Su investigación se centra en el desarrollo de fármacos dirigidos para el cáncer de ovario y en abordar la resistencia a la quimioterapia en los cánceres de ovario y útero.
에테르나 테라퓨틱스 (NASDAQ: ERNA)는 이사회에 엘레나 랏너 박사를 임명했습니다. 랏너 박사는 예일대 의과대학 산부인과 및 생식과학부의 교수로서, 에테르나가 난소암과 싸우는 전략적 방향을 안내할 것입니다.
이번 임명은 에테르나가 MD 앤더슨 암 센터와 최근 협력하여 난소암과 유방암을 위한 새로운 치료법 개발에 초점을 맞춘 것입니다. 회사의 주요 후보인 ERNA-101은 면역세포의 침투와 활성화를 개선하여 종양에 대한 면역 반응을 강화하도록 설계된 세포 치료제입니다.
랏너 박사는 현재 조기 난소암 발견 프로그램인 Discovery to Cure의 책임자로 재직 중이며, 2024년 데이비드와 신디 레펠 클리니컬 엑설런스 상을 포함하여 여러 차별화된 수상을 받았습니다. 그녀의 연구는 난소암을 치료하기 위한 표적 약물 개발과 난소암 및 자궁암에서의 화학요법 저항성 문제를 다룹니다.
Eterna Therapeutics (NASDAQ: ERNA) a nommé Dr. Elena Ratner au sein de son Conseil d'Administration. Dr. Ratner, professeur à l'École de Médecine de l'Université de Yale au Département d'Obstétrique, de Gynécologie et des Sciences de la Reproduction, guidera l'orientation stratégique d'Eterna dans la lutte contre le cancer de l'ovaire.
Cette nomination fait suite à la récente collaboration d'Eterna avec le MD Anderson Cancer Center, axée sur le développement de thérapies novatrices pour les cancers de l'ovaire et du sein. Le candidat principal de l'entreprise, ERNA-101, est une thérapie cellulaire conçue pour renforcer la réponse du système immunitaire contre les tumeurs en améliorant la pénétration et l'activation des cellules immunitaires.
Dr. Ratner occupe actuellement le poste de directrice du programme Discovery to Cure Early Ovarian Cancer Detection et a reçu des distinctions notables, y compris le Prix d'Excellence Clinique David et Cindy Leffell 2024. Sa recherche se concentre sur le développement de médicaments ciblés pour le cancer de l'ovaire et sur la gestion de la résistance à la chimiothérapie dans les cancers de l'ovaire et de l'utérus.
Eterna Therapeutics (NASDAQ: ERNA) hat Dr. Elena Ratner in seinen Vorstand berufen. Dr. Ratner, Professorin an der Yale University School of Medicine im Fachbereich Geburtshilfe, Gynäkologie und Reproduktionswissenschaften, wird die strategische Ausrichtung von Eterna im Kampf gegen Eierstockkrebs leiten.
Diese Ernennung folgt auf die kürzliche Zusammenarbeit von Eterna mit dem MD Anderson Cancer Center, die sich auf die Entwicklung neuer Therapien für Eierstock- und Brustkrebs konzentriert. Der Hauptkandidat des Unternehmens, ERNA-101, ist eine Zelltherapie, die darauf abzielt, die Immunantwort gegen Tumore zu verbessern, indem die Infiltration und Aktivierung von Immunzellen gesteigert wird.
Dr. Ratner ist derzeit Direktorin des Programms Discovery to Cure Early Ovarian Cancer Detection und hat bemerkenswerte Auszeichnungen erhalten, darunter den 2024 David and Cindy Leffell Clinical Excellence Award. Ihre Forschung konzentriert sich auf die Entwicklung zielgerichteter Medikamente gegen Eierstockkrebs und die Bekämpfung der Chemotherapieresistenz bei Eierstock- und Gebärmutterkrebs.
- Strategic appointment of renowned ovarian cancer expert to guide ERNA-101 development
- Recent collaboration established with MD Anderson Cancer Center for cancer research
- Lead candidate ERNA-101 shows promise in enhancing immune response against tumors
- None.
World-renowned researcher brings expertise in obstetrics and gynecology from Yale University to advance Eterna’s lead indication in ovarian cancer
CAMBRIDGE, Mass., Jan. 09, 2025 (GLOBE NEWSWIRE) -- Eterna Therapeutics (Nasdaq: ERNA), a leader in cell therapies for the treatment of advanced solid tumors, today announced the appointment of Elena Ratner, M.D., M.B.A, to the Board of Directors.
Dr. Ratner will spearhead the strategic direction of Eterna’s efforts to combat ovarian cancer, leveraging her extensive expertise in obstetrics, gynecology, and reproductive sciences. Under her leadership, the company aims to accelerate advancements in innovative therapies targeting these high-priority areas in women's health. This direction is bolstered by Eterna’s recent collaboration with MD Anderson Cancer Center. Announced last month, the partnership underscores Eterna's commitment to groundbreaking research in women’s health, focusing on the development of novel approaches to improve outcomes for patients affected by ovarian and breast cancers.
“I’m excited to join Eterna and contribute my passion for fighting ovarian cancer to the company’s inspiring mission,” said Dr. Ratner. “Treating ovarian cancer is extremely challenging, as it is often resistant to treatment and has a high rate of recurrence. Eterna’s scientific data has been very impressive and shows a lot of promise. I’m eager to work closely with the team to advance ERNA-101 in ovarian cancer.”
ERNA-101 is a cell therapy that enhances the immune system's response against tumors, improving immune cell infiltration and activation.
“Dr. Ratner is widely recognized as a trailblazer in ovarian cancer research and treatment, with a reputation for groundbreaking contributions that have advanced the field,” said James Bristol, Ph.D., Chairman of the Board at Eterna Therapeutics. “Her unparalleled expertise and strategic insights will be invaluable as we continue to drive innovation and deliver transformative solutions for patients.”
Dr. Ratner serves as a Professor in the Department of Obstetrics, Gynecology, and Reproductive Sciences at Yale University School of Medicine. She is involved in many research initiatives to develop new targeted drugs for ovarian cancer, as well as research on reversing chemotherapy resistance in ovarian and uterine cancers. She also serves as the Director of the Discovery to Cure Early Ovarian Cancer Detection program. She is the recipient of many awards, including the 2024 David and Cindy Leffell Clinical Excellence Award and the 2015 Yale Cancer Center Award for Clinical Excellence.
About Eterna Therapeutics
Eterna Therapeutics is a publicly traded, preclinical-stage company focused on developing highly innovative, effective, safe off-the-shelf synthetic iMSC therapies. Eterna’s lead product ERNA-101 is an allogeneic pro-inflammatory cytokine (IL-7/IL-15)-secreting iMSC. ERNA-101 capitalizes on the intrinsic tumor-homing and infiltration ability of MSCs to slip through the tumor’s defenses and to deliver potent pro-inflammatory factors directly to the tumor microenvironment (TME), limiting systemic exposure and potential toxicity while unleashing potent anti-cancer immune responses including enhancement of T-cell anti-tumor activity. The company’s initial focus is to develop ERNA-101 in platinum-resistant ovarian cancer (PROC). The company is also investigating ERNA-102, anti-inflammatory cytokine (IL-10)-secreting iMSCs in inflammatory/auto-immune disorders like rheumatoid arthritis. The company is actively seeking strategic partnerships to co-develop or out-license therapeutic assets and engage with potential collaborators to expand developmental opportunities. For more information, please visit https://www.eternatx.com/.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are intended to be covered by the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements, in some cases, can be identified by terms such as "believe," "may," "will," "estimate," "continue," "anticipate," "design," "intend," "expect," "could," "plan," "potential," "predict," "seek," "should," "would," "contemplate," "project," "target," "objective," or the negative version of these words and similar expressions. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause Eterna's actual results, performance or achievements to be materially different from future results, performance or achievements expressed or implied by the forward-looking statements in this press release, including, without limitation, risks and uncertainties related to: progress and possible outcomes of the Company’s lead research project, ERNA-101, and future research projects. Forward-looking statements are based upon Eterna's current expectations and involve assumptions that may never materialize or may prove to be incorrect. All forward-looking statements are expressly qualified in their entirety by these cautionary statements. For a detailed description of Eterna's risks and uncertainties, you are encouraged to review its documents filed with the SEC including its recent filings on Form 8-K, Form 10-K and Form 10-Q. You are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date on which they were made. Eterna does not undertake any obligation to update the forward-looking statements contained herein to reflect events that occur or circumstances that exist after the date hereof, except as required by applicable law.
Media & Investor Relations Contact
FAQ
What is the significance of Dr. Elena Ratner joining ERNA's Board of Directors?
How does Eterna Therapeutics' ERNA-101 work against cancer?
What is the recent partnership between ERNA and MD Anderson Cancer Center?
What are Dr. Ratner's key achievements and current roles relevant to ERNA?
